Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 4, 2010, Pages 347-352

  Farlow, Martin R ^a   Cummings, Jeffrey L ^b   Olin, Jason T ^c   Xiangyi Meng, ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Cognition; Language; Memory; Praxis; Rivastigmine

Indexed keywords

PLACEBO; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; SCORING SYSTEM; TREATMENT RESPONSE; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; LANGUAGE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LANGUAGE; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77953635746     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317510365344     Document Type: Article

References (21)

1. Davies P., Maloney AJ Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 ; 2 (8000). 1403.
2. Rosenstein LD Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev. 1998 ; 8 (3). 109-167.
3. Cummings JL Alzheimer's disease. N Engl J Med. 2004 ; 351 (1). 56-67.
4. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 ; 141 (11). 1356-1364.
5. Winblad B., Brodaty H., Gauthier S., et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success ? Int J Geriatr Psychiatry. 2001 ; 16 (7). 653-666.
6. Benge JF, Balsis S., Geraci L., Massman PJ, Doody RS How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Dement Geriatr Cogn Disord. 2009 ; 28 (1). 63-69.
7. Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 ; 318 (7184). 633-638.
8. Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007 ; 78 (10). 1056-1063.
9. Schneider LS, Anand R., Farlow MR Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998 ; 1 (suppl 1). S26 - S34.
10. Corey-Bloom J., Anand R., Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998 ; 1 (2). 55-65.
11. Birks J., Grimley Evans J., Iakovidou V., Tsolaki M., Holt FE Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 ;(2). CD001191.
12. Reitz C., Honig L., Vonsattel JP, Tang MX, Mayeux R. Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry. 2009 ; 80 (7). 715-721.
13. Mohs RC, Knopman D., Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997 ; 11 (suppl 2). S13 - S21.
14. Olin J., Schneider L. Assessing response to tacrine using the factor analytic structure of the Alzheimer's Disease Assessment Scale (ADAS) cognitive subscale. Int J Geriatr Psychiatry. 1995 ; 10 (9). 753-756.
15. Venneri A., Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport. 2002 ; 13 (1). 83-87.
16. Adler G., Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001 ; 43 (4). 273-276.
17. Nordberg A., Darreh-Shori T., Svensson A., Guan Z. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci. 2001 ; 187 (suppl 1). P0144.
18. Bullock R., Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res. 2007 ; 4 (3). 277-293.
19. Raskind MA, Peskind ER, Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000 ; 54 (12). 2261-2268.
20. Rogers SL, Farlow MR, Doody RS, Mohs R., Friedhoff LT A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 ; 50 (1). 136-145.
21. Rockwood K., Mintzer J., Truyen L., Wessel T., Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 ; 71 (5). 589-595.